- NCIt
- C121792
Loading cancer entity…
Loading cancer entity…
Clinical trials
5 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06683846 | Ivonescimab in the Treatment of Multiple Advanced Tumors | recruiting | Phase 2 | 400 | Fudan UniversityOTHER | 1 | Aug 24, 2025 | clinicaltrials |
| NCT02494570 | A Phase 2 Study of Nab-sirolimus (ABI-009) in Patients With Advanced Malignant PEComa(AMPECT) | completed | Phase 2 | 34 | Aadi Bioscience, Inc.INDUSTRY | 1 | Apr 7, 2023 | clinicaltrials |
| NCT01690871 |
| A Phase II Study of Orally Administered BEZ235 Monotherapy in Patients With Metastatic or Unresectable Malignant PEComa |
| withdrawn |
| Phase 2 |
| 0 |
| Novartis PharmaceuticalsINDUSTRY |
| 1 |
| Aug 2, 2013 |
| clinicaltrials |
Data updated 22 days agoSource updated Aug 24, 2025source: clinicaltrials